Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ITVISMA safely and effectively. See full prescribing information for ITVISMA. ITVISMA® (onasemnogene abeparvovec-brve) suspension, for intrathecal injection Initial U.S. Approval: 2025
Medication labelWhy this: Advisory · dailymed-prescription
ITVISMA is indicated for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in survival motor neuron 1 (SMN1) gene.
- generic_name
- onasemnogene abeparvovec-brve
- product_names
- onasemnogene abeparvovec-brve
- ndc
- 71894-200, 71894-200-01, 71894-200-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en